Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Big Pharma

Australia’s ‘coercive’ news media rules are the latest targets of US trade ire

As the United States recalibrates its trade policies to combat what the Trump administration sees as “unfair” treatment by other countries, two significant industries have complained to US regulators about their treatment in Australia.

The Conversation

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

MarketBeat

My son’s rare disease diagnosis spurred me to ditch Big Pharma for a biotech startup

Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

Big Pharma’s Monopoly On Ozempic Threatens Access To Diabetes Drug In Communities Of Color

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

Zenger

Catalyst's New CEO Has Big Ideas For The Small Biotech

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

Investors Business Daily

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

Investors Business Daily

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Investors Business Daily

Big Pharma slowed vaccine development

A vaccine against tuberculosis has never been closer to reality. But development slowed due to corporate interests

Salon

Draft patent amendment rules undermine pre-grant opposition

Draft patent rules threaten pre-grant opposition, a key public health safeguard. Big pharma seeks to remove essential safeguards from India’s patent laws, creating needless hurdles in pre-grant opposition. Draft rules introduce variable fees, power to determine maintainability of representation by individuals/groups. This threatens access to quality-assured, affordable generics & extends…

The Hindu

Amy Klobuchar on Biden's biggest win

Minnesota senator and anti-monopoly crusader explains how fixing Medicare's drug problem will help everybody

Salon

With a pharmacare bill on the horizon, Big Pharma’s attack on single-payer drug coverage for Canadians needs a fact check

Health Minister Mark Holland announced in August that the federal government intends to introduce pharmacare legislation in the fall. Now the battle lines are being drawn.

The Conversation

South Africa ‘held to ransom’ by big pharma, overcharged for COVID vaccines

J&J, Pfizer charged South Africa between 15 and 33 percent more for COVID vaccine doses, contracts reveal.

Al Jazeera

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

The Independent UK

Revolving Door: DEA’s No.2 quits amid reports of previous consulting work for Big Pharma

The U.S. Drug Enforcement Administration’s second-in-command has quietly stepped down amid reporting by The Associated Press that he previously consulted for a pharmaceutical distributor sanctioned for a deluge of suspicious painkiller shipments and did similar work for the drugmaker that became the face of the opioid epidemic: Purdue Pharma

Salon

Scam science: How to outsmart the con

Authors of "Nobody's Fool" say "There's an unending arms race of people coming up with new ways to try to scam us"

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Get all your
news in one place.

100’s of premium titles.
One news app.

Los Angeles Times

Michael Hiltzik: Merck says it's being 'coerced' into negotiating its drug prices with Medicare. That's nonsense

No one really expected the pharmaceutical industry to lie down and take it when Congress authorized Medicare to start negotiating prices of the prescription drugs it buys for enrollees.

PC Gamer

Naheulbeuk's Dungeon Master brings Two Point Hospital's HR management to Dungeon Keeper

Big Sorcery is the new Big Pharma, but the hours are murder.

Salon

Merck sues to block lower Medicare costs

The company claims that the plan to allow Medicare to negotiate drug prices violates the First and Fifth Amendments

Investors Business Daily

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Reason

Did Fox Really Fire Tucker Carlson for Crossing the 'Red Line' of Criticizing Big Pharma, as RFK Jr. Claims?

If so, the network failed to enforce the supposed rule before and after cancelling its top-rated host.

Businessweek

AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

Chicago Sun-Times

Experts warn new weight loss medications carry long-term concerns

Some doctors, psychologists and eating disorder experts worry these new medications, originally developed to treat diabetes, could become a problem long-term.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations